MEDI 8968

Drug Profile

MEDI 8968

Alternative Names: AMG-108; Anti-IL-1R MAb; MEDI-8968

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; MedImmune
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; Hidradenitis suppurativa; Osteoarthritis; Rheumatoid arthritis; Type 2 diabetes mellitus

Most Recent Events

  • 21 Jul 2016 AstraZeneca terminates a phase II trial in Hidradenitis suppurativa in USA (SC) (NCT01838499)
  • 31 Jul 2014 Discontinued - Phase-II for Chronic obstructive pulmonary disease in USA, United Kingdom, Bulgaria, Hungary, Czech Republic, Latvia, Lithuania, Poland, Ukraine and the Philippines (SC)
  • 31 Jul 2014 Discontinued - Phase-II for Hidradenitis suppurativa in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top